Compare RRR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRR | ADPT |
|---|---|---|
| Founded | 1976 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2015 | 2019 |
| Metric | RRR | ADPT |
|---|---|---|
| Price | $54.68 | $24.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $69.69 | $17.78 |
| AVG Volume (30 Days) | 723.0K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | 23.32 | ★ 63.89 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $2,011,483,000.00 | $276,976,000.00 |
| Revenue This Year | $3.41 | $3.98 |
| Revenue Next Year | $4.62 | $22.72 |
| P/E Ratio | $40.09 | ★ N/A |
| Revenue Growth | 3.74 | ★ 54.77 |
| 52 Week Low | $50.52 | $12.00 |
| 52 Week High | $68.99 | $26.87 |
| Indicator | RRR | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 27.78 | 49.67 |
| Support Level | $51.19 | $23.92 |
| Resistance Level | $59.34 | $26.51 |
| Average True Range (ATR) | 1.56 | 1.02 |
| MACD | -0.34 | -0.30 |
| Stochastic Oscillator | 5.23 | 24.46 |
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.